Skip to main content
. Author manuscript; available in PMC: 2011 Jul 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2010 Jun 15;19(7):1848–1854. doi: 10.1158/1055-9965.EPI-10-0101

Table 2.

Associations between three most significant SNPs in 8q24 cancer risk regions and serum testosterone measures in 563 male subjects

Serum Androgen SNP (major/minor alleles) Location (bp) MAF1 β2 SE2 P2 P3 P4
Total testosterone rs12334903(C) 128,119,695 0.40 −0.10 0.03 8.69×10−4 0.023 0.100
rs1456310(A) 128,121,615 0.43 −0.10 0.03 1.13×10−3 0.030 0.127
rs980171(G) 128,123,704 0.39 −0.11 0.03 3.14×10−4 9.60×10−3 0.039
Bioavailable testosterone rs12334903(C) 128,119,695 0.40 −0.09 0.03 3.73×10−4 0.012 0.049
rs1456310(A) 128,121,615 0.43 −0.08 0.02 6.28×10−4 0.019 0.076
rs980171(G) 128,123,704 0.39 −0.09 0.03 1.66×10−4 4.95×10−3 0.023
1

MAF = minor allele frequency

2

Based on age-adjusted linear regression analysis of log-transformed androgen and SHBG measurements using SNPs in an additive genetic model

3

Adjusted for multiple comparisons using a parametric bootstrap procedure with 20,000 replicates generated under the null for the evaluation of significance levels accounting for all 38 SNPs tested within the prostate cancer region 2

4

Adjusted for multiple comparisons using a parametric bootstrap procedure with 20,000 replicates generated under the null for the evaluation of significance levels accounting for all 164 SNPs tested in 8q24 region